Morepen Laboratories Secures ₹825 Cr CDMO Mandate, Boosting Global Pharma Ambitions

Morepen Laboratories' CDMO mandate is valued at approximately ₹825 crore ($91 million).
This significant multi-year deal marks a strategic entry into the high-growth CDMO segment.

What just happened

Morepen Laboratories has announced a substantial multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately ₹825 crore ($91 million). This development signifies a key expansion into the burgeoning CDMO sector for the Indian pharmaceutical firm.

The company expects supplies to commence within the next 4 to 5 months, with the actual execution of the mandate scheduled to begin in the first quarter of the upcoming financial year.

Management views this award as a critical validation of their quality systems and execution capabilities, highlighting it as a major milestone in the company's growth trajectory.

Why this matters

This substantial CDMO mandate represents a significant step for Morepen Laboratories, validating its manufacturing capabilities and quality accreditations, including USFDA and WHO-GMP certifications. The agreement underscores the company's strategic pivot to capitalize on the global demand for contract manufacturing services in the pharmaceutical industry.

By securing one of the largest mandates in its history, Morepen aims to enhance its global manufacturing footprint and create long-term value for its stakeholders. This expansion into CDMO services leverages its existing expertise in Active Pharmaceutical Ingredients (APIs).

The backstory (grounded)

Morepen Laboratories has established itself as a significant player in the pharmaceutical space, known for its API production and a strong portfolio of medical devices. The company holds accreditations from major regulatory bodies like the USFDA, WHO GMP, and EU GMP, facilitating its exports to over 80 countries.

Recently, Morepen has been focusing on expanding its domestic formulations business, including plans to significantly grow its salesforce. The company has also been active in international markets, incorporating new subsidiaries in Dubai to market its medical devices.

While the company has a history of robust quality compliance, including clearing USFDA inspections without adverse observations, it has also faced regulatory scrutiny. In December 2025, it received a GST show-cause notice for alleged excess refund claims of ₹117.94 crore, though a stay was granted by the Himachal Pradesh High Court on January 6, 2026.

What changes now

• Revenue Diversification: The CDMO mandate is expected to significantly boost revenue streams beyond Morepen's existing API and medical device businesses.
• Global Footprint Expansion: This contract validates Morepen's capabilities for international clients, potentially opening doors for more global partnerships.
• Capacity Utilization: The mandate will likely drive higher utilization of its manufacturing facilities, enhancing operational efficiencies.
• Validation of Quality Systems: Successful execution will further strengthen Morepen's reputation for quality and reliability in regulated markets.
• Focus on High-Growth Segment: It reinforces the company's strategic push into the lucrative and expanding CDMO market.

Risks to watch

• Execution Risk: Successfully scaling up and delivering on the multi-year contract within the stipulated timelines will be crucial.
• Regulatory Compliance: Maintaining high standards of quality and compliance as per international pharmaceutical norms is paramount for long-term success in the CDMO space.
• GST Show-Cause Notice: While a stay has been granted, the ongoing legal proceedings related to the ₹117.94 crore GST refund claim remain a point of attention until resolved.
• Forward-Looking Statement Caveats: As with any such announcement, the press release itself notes that forward-looking statements are subject to risks and uncertainties that could materially impact actual results.

Peer comparison

Morepen Laboratories' move into a significant CDMO mandate places it alongside established Indian players in this segment.

• Laurus Labs is actively growing its CDMO business, aiming for it to become a dominant revenue contributor, backed by investments in enhanced capabilities.
• Divi's Laboratories is a leader in custom synthesis, serving major global pharmaceutical innovators and focusing on complex APIs and intermediates.
• Suven Pharmaceuticals (now Cohance Lifesciences) is also targeting substantial revenue growth through its CDMO offerings, focusing on specialized molecules.

Morepen's existing API strengths and USFDA certifications provide a strong foundation for competing in this space.

Context metrics (time-bound)

• The CDMO mandate is valued at approximately ₹825 crore ($91 million) and is multi-year in nature.
• Supplies are expected to commence within 4-5 months from the announcement date.
• Execution of the mandate is scheduled to begin in Q1 of the following financial year.

What to track next

• Commencement of Supplies: Monitor the timely start of product shipments within the next 4-5 months.
• Execution Milestones: Track the progress of the CDMO mandate execution starting from Q1 of the next financial year.
• Further CDMO Engagements: Look for any new announcements regarding additional CDMO contracts or expansions in this segment.
• Financial Performance: Observe how this new revenue stream influences Morepen's overall financial results in upcoming quarters.
• Resolution of GST Matter: Keep an eye on the outcome of the GST show-cause notice proceedings.